GENZYME CORPORATION for GENZYME CORPORATION
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Neglected Disease Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Copyright/Patent/Trademark CPT
S. 515, Patent Reform Act of 2009 HR. 1260, Patent Reform Act of 2009 HR. 1548 Pathway for Biosimilars Act of 2009 HR. 1427, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 726, Promoting Innovation and Access to Life-Saving Medicines Act, Follow-on Biologics S. 610 Patent Reform Act of 2009 Senate draft bill Biologics Price Competition and Innovation Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Medicare/Medicaid MMM
H.R. 444, 340B Program Improvement and Integrity Act of 2009, 340B drug price expansion H.R. 1832 Medicare Prescription Drug Affordability Act of 2009 S. 266 Medicare Prescription Drug Gap Reduction Act of 2009 S. 301, Physician Payments Sunshine Act of 2009 Comparative Effectiveness ESRD "bundling issues" and ESRD drug reimbursement issues Medicare prescription drug benefit CPT Coding decisions and HCPCS coding decisions Reimbursement for Part B Drugs administered in hospital out patient departments, dialysis centers and physician officers Physicians fee schedule payment rates for lab tests. Medicaid rebates MIPPA Technical Corrections H.R. 1699 Patient Access to Critical Lab Test H.R. 1452 Medicare Clinical Diagnostic Laboratory Fee Schedule Modernization Act of 2009 Reimbursement /Payment laboratory tests S. 275 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 2 Children's Health Insurance Program Reauthorization Act of 2009 H.R. 676 - US National Health Care Act or the Expanded and Improved Medicare for All Act Least Costly Alternative (LCA) policy for viscosupplements
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Budget/Appropriations BUD
H.R. 1 American Recovery and Reinvestment Act of 2009 S. Con. Res. 13 H. Con. Res. 85 S. 350 American Recovery and Reinvestment Act of 2009
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Pharmacy PHA
H.R. 1548, Pathway for Biosimalars Act of 2009 H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act S. 726 Promoting Innovation and Access to Life-Saving Medicines Act S. 301 Physician Payments Sunshine Act of 2009 Neglected Disease Issues Issues related to Drug Safety, Generic Biologics & Drug Approvals Importation. H.R. 1298, Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation. S.525, "Pharmaceutical Market Access & Drug Safety Act of 2009" - Importation H.R. 759 Food and Drug Administration Globalization Act of 2009
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Medical/Disease Research/Clinical Labs MED
H.R. 1452, Medicare Clinical Diagnostic laboratory Fee Schedule Modernization Act of 2009 Reimbursement for clinical lab services under Medicare
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.